The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
To read the full story
Related Article
- Novartis Rolls Out Cosentyx 300 mg Pen in Japan
December 1, 2022
BUSINESS
- Xtandi Plus Leuprolide Meet PIII Goal in Non-Metastatic Prostate Cancer: Astellas
March 20, 2023
- Takeda Updates Qdenga Peak Sales Estimate to US$1.6-2 Billion
March 17, 2023
- Fujifilm to Make Foray into Drug Discovery CRO Business
March 17, 2023
- Twymeeg No 1 in GP Promotion in January, Dayvigo Most Pitched for HP: Intage
March 17, 2023
- CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
March 17, 2023
“Balance” seems to be the keyword for the next drug pricing reform in FY2024. Japan now appears ready to seek a better balance between evaluating innovative medicines and taking tough measures against companies dependent on long-listed products (LLPs) and generic…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…